FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer

What was approved and why does it matter?

The FDA approved the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) for adult patients with advanced renal cell carcinoma with a clear cell component following treatment with a PD-1 or PD-L1 inhibitor. This marks the first-ever approved combination of a HIF-2α inhibitor and a multi-targeted VEGFR-TKI — two distinct biological mechanisms working together in a dual oral regimen.

What did the clinical trial show?

The approval is based on the Phase 3 LITESPARK-011 trial, which compared WELIREG plus LENVIMA against cabozantinib — the current standard of care in this setting — in 747 patients. At a pre-specified interim analysis, WELIREG plus LENVIMA reduced the risk of disease progression or death by 26% versus cabozantinib, with a median progression-free survival of 14.6 months versus 10.6 months. The objective response rate was 53% versus 40% for cabozantinib. The overall survival endpoint did not meet statistical significance at the final analysis.

Why is this significant for Merck?

WELIREG now holds FDA-approved indications across four distinct settings: VHL disease, locally advanced or metastatic pheochromocytoma or paraganglioma, adjuvant ccRCC in combination with KEYTRUDA, and now previously treated advanced ccRCC with LENVIMA. That four-indication footprint — built on a single HIF-2α inhibitor mechanism — is one of the most successful multi-indication platform strategies in oncology this decade. It is also directly relevant to Merck's need to build revenue diversity ahead of KEYTRUDA's patent cliff.

FDA Approves Onswik — the First Once-Weekly Basal Insulin for Type 2 Diabetes

What is Onswik and what was approved?

The FDA approved Onswik (insulin efsitora alfa-gobe), Eli Lilly's once-weekly basal insulin, for adults with type 2 diabetes. It is designed to replace daily basal insulin injections — reducing the injection burden by more than 300 injections per year — while maintaining comparable glycemic control. This is Lilly's fourth global approval for Onswik.

What does this mean competitively?

Novo Nordisk's Awiqli (insulin icodec) received FDA approval in March 2026 as the first once-weekly basal insulin. Onswik's approval creates a direct head-to-head competition between the two companies in a new category — once-weekly basal insulin — that didn't exist in the US market six months ago. Both drugs are approved for Type 2 diabetes with similar non-inferiority data versus daily basal insulin. The clinical differentiation will be established over time through head-to-head data, access negotiations, and real-world outcomes.

Who is the primary patient population?

Onswik is designed for adults with Type 2 diabetes who need basal insulin, particularly those who are insulin-naïve and have not achieved glycemic goals on oral therapies or GLP-1s. Reducing the daily injection burden is both a clinical and adherence benefit — patients who are reluctant to initiate insulin due to injection frequency now have a once-weekly alternative that may lower that barrier to starting therapy.

InnoCare and Lilly's $3.35 Billion Research Collaboration

What did InnoCare and Lilly announce?

InnoCare Pharma and Eli Lilly entered a strategic research collaboration and license agreement under which InnoCare will use its proprietary drug discovery platform to identify and advance compounds against up to five undisclosed targets selected by Lilly. InnoCare is eligible to receive up to $3.35 billion in total consideration, including a $100 million upfront payment, plus tiered royalties.

What makes this deal structurally distinctive?

Unlike most China-originated pharma deals, which involve licensing a specific asset that has already demonstrated proof-of-concept, the InnoCare collaboration is a platform research deal — Lilly is paying for InnoCare's discovery capabilities across multiple undisclosed targets simultaneously. The deal is structurally nearly identical to Lilly's earlier collaboration with Abbisko, which also used a Chinese biotech's discovery platform to advance compounds against Lilly-selected targets. Together the two deals reveal that Lilly has developed a standardized template for Chinese biotech platform collaborations that it is now deploying at scale.

How does this fit into Lilly's broader China strategy?

Lilly is now simultaneously executing multiple China partnership models: the InnoCare platform collaboration, the Abbisko platform collaboration, the Insilico AI drug discovery partnership, and the Innovent Biologics commercial cooperation. The depth and diversity of these simultaneous engagements signals that China has become a structural component of Lilly's R&D strategy rather than an opportunistic supplement to it.

Three Platform Deals: Nanexa/Novo, Earendil Labs/Genentech, Atavistik Bio/Roche

What were the three deals announced?

Three platform-technology deals were announced this week. Nanexa AB licensed its Pharmashell drug delivery platform to Novo Nordisk for use in up to five peptide programs targeting obesity, Type 2 diabetes, and other cardiometabolic indications, with total potential payments exceeding $1.33 billion. Earendil Labs entered a research collaboration with Genentech to discover and develop bispecific antibody programs in oncology, with $55 million upfront and total potential value exceeding $1.5 billion. Atavistik Bio struck a collaboration with Roche to discover novel small molecule therapeutics against multiple cardiovascular, renal, and metabolic disease targets using its allosteric drug discovery platform, with $70 million upfront and total potential milestone payments of up to $1.9 billion.

What does the Nanexa/Novo deal tell us about Novo's strategy?

The Pharmashell technology platform uses atomic layer deposition to apply ultra-thin inorganic coatings to individual drug particles, enabling controlled and sustained release that supports monthly and quarterly injection profiles. For Novo, this deal is about moving beyond weekly GLP-1 injections — the Orbis macrocycle collaboration, the Nanexa delivery platform, and the Anthropic AI discovery partnership are all bets on the same thesis: that the next wave of competitive differentiation in cardiometabolic disease will come from less frequent dosing enabled by better drug delivery.

What is the Earendil Labs AI platform?

Earendil Labs has built an AI-driven high-throughput biology platform that integrates AI directly into biologics R&D — from predictive protein modeling and generative protein design to rapid experimental validation. The collaboration with Genentech deploys that platform for bispecific antibody discovery in oncology. Genentech simultaneously licensed DualityBio's DUPAC payload platform for next-generation ADCs and expanded its C4 Therapeutics protein degradation collaboration this week — revealing a Roche group that is systematically building next-generation biology discovery capabilities across multiple external platforms simultaneously.

What does Atavistik Bio's allosteric platform offer?

Atavistik Bio's Amps platform identifies cryptic, biologically relevant binding pockets — sites on protein targets that conventional drug discovery misses — to develop differentiated small molecules against therapeutically important targets that have historically been difficult to modulate. For Roche, which is simultaneously advancing CT-388, a dual GLP-1/GIP receptor agonist, through Phase 3, the allosteric cardiovascular and metabolic disease collaboration adds a discovery capability that complements its clinical pipeline with a longer-horizon research bet.

Novartis and BoomRay's $900 Million Radioligand Therapy License

What did Novartis acquire?

Novartis agreed to pay BoomRay Pharmaceuticals up to $900 million for exclusive global rights to an undisclosed preclinical radioligand therapy asset. BoomRay is a Suzhou-based clinical-stage company focused on next-generation radiopharmaceuticals. The deal adds to Novartis's existing RLT portfolio anchored by Pluvicto and Lutathera.

Why is the timing significant?

The BoomRay deal arrives at exactly the moment Novartis is under the most significant shareholder pressure in years, following two consecutive Phase 3 failures from acquired assets and a $30 billion market cap loss. Eight shareholders have called for board governance changes — yet Novartis is simultaneously continuing to execute its RLT platform strategy with a new Chinese biotech licensing deal. That juxtaposition signals that the board governance debate has not slowed Novartis's pipeline-building activity in its highest-conviction platform.

How does this fit into the global radioligand therapy landscape?

The global radiopharmaceutical market is expected to nearly triple from $9 billion in 2023 to $26.5 billion by 2031. Novartis's strategy of layering external RLT licensing — Mariana Oncology for $1 billion, BoomRay for up to $900 million — onto its internal Pluvicto and Lutathera franchise reflects a deliberate multi-source platform-building approach. The RLT space's half-life-driven logistics and dual pharmaceutical-radiation regulatory requirements mean that manufacturing infrastructure and supply chain expertise are as competitively significant as the assets themselves — and Novartis has built more of that infrastructure than any other company through its Denton, Texas RLT manufacturing facility.

Novo CEO Considers Direct NYSE Listing

What did Doustdar say?

Novo Nordisk CEO Mike Doustdar told the Financial Times he is open to considering a direct listing of the company's shares on the New York Stock Exchange, which would replace the American depositary receipt structure US investors currently use to trade Novo's stock. He characterized his posture as "maybe" rather than "no," noting the company's investor base has shifted significantly beyond Scandinavia over the past two decades and that the US market now accounts for more than half of revenue. No formal process is underway and no timetable has been announced.

Why does this matter?

A direct NYSE listing would give US investors direct access to Novo shares rather than through depositary receipts, potentially increasing liquidity and simplifying access for the US-based institutional investors who are increasingly central to Novo's shareholder base. AstraZeneca pursued a similar listing structure change earlier this year, and Doustdar's openness to the idea places Novo within a broader pattern of European pharmaceutical companies reconsidering how they access US capital markets as American sales and American investors take on greater weight in their businesses.

What does it signal about the competitive context?

The listing discussion surfaces against a backdrop of competitive strain — Novo's shares have fallen more than 70% from their peak, even as Lilly's have climbed. A direct NYSE listing is partly a signal of strategic seriousness about the US market at a moment when Lilly's commercial execution, direct-to-consumer strategy, and pipeline depth are generating more investor confidence than Novo's. Doustdar's openness to the idea is one more data point in a pattern of moves designed to demonstrate that Novo is a more US-centric company than its Danish headquarters might suggest.

Nine European Drugmakers Warn of a "Slow Agony" of Decline

Who signed the letter and what did it say?

The chairs of AstraZeneca, GSK, Novo, Novartis, Roche, Sanofi, Boehringer Ingelheim, Chiesi, and Ipsen published an open letter calling on the European Union and its member states to sharply increase spending on medicines, accelerate clinical trials, strengthen intellectual property protections, and give member states greater fiscal flexibility to invest in health. The letter explicitly invokes Mario Draghi's warning that without urgent action, strategic sectors including pharmaceuticals face a "slow agony" of decline.

How far behind has Europe actually fallen?

The data in the letter is stark. Approximately 40% of new therapies never reach European patients, and those that do arrive after patients wait nearly 600 days. Europe's share of global pharmaceutical R&D has fallen to 31% from 43% in 1990. Its share of commercial clinical trials has been cut in half to 9% over the past decade. China has overtaken Europe in clinical trials, pharmaceutical patents, and new medicine development. Europe spends about 1% of GDP on pharmaceuticals, compared to 2% in the United States and 1.8% in China. Over the past two years alone, more than $600 billion in pharmaceutical investment has been announced in the United States and China combined.

Why does this connect to the Novo NYSE listing story?

The two stories are directly related — Novo's openness to a direct US listing is a concrete commercial expression of the investment migration the open letter is warning about. If the CEO of Europe's most valuable pharmaceutical company is actively considering moving its primary listing from Copenhagen to New York, that is not an abstract policy question. It is a visible and measurable consequence of the investment environment the nine chairs are calling on EU governments to address.

What would closing the gap require?

The chairs estimate that closing Europe's clinical trial gap with China and the United States alone could unlock $70 billion in economic activity and 82,000 jobs. Bringing a single innovative medicine to patients takes more than a decade and approximately $4 billion in at-risk investment — a risk profile that requires a regulatory, IP, and reimbursement environment willing to reward that investment over the long horizon it demands. The chairs argue that European governments have historically treated medicines as a cost to be suppressed rather than an investment to be made, and that reversing that posture before the gap becomes permanent is the most urgent policy priority the EU faces in life sciences.